Newly floated Cambridge BioTech company formed in 2007 has over 300 customers including Astra Zeneca.

Floated at 180p.

http://en.wikipedia.org/wiki/Horizon_Discovery

Results out this morning.

The future seems to look extremely promising:

Post-period highlights

-- Strong start to 2017, with Q1 revenue up c25% year on year, underpinning guidance of FY17 revenue between GBP30-35m

-- Immuno-oncology set to be a powerful growth driver generating GBP1.5m in current and ongoing Products and Services in FY17 to date, c40% increase over FY16, and >10 novel drug targets and molecules in development for future or via joint-ventures or spin-outs

-- Exclusive licenses for the use of a novel transposon-based gene editing platform, providing a unique approach to gene editing and DNA delivery and enabling the use of gene editing in bioproduction, diagnostics products and for the first time directly as a cell or gene therapy

-- Signing of a Master Services Agreement with a top three global pharmaceutical company, extending support for their drug discovery and development efforts to Horizon's full suite of services

Share price up more than 50% in 10 weeks since that last post (up 100p)